Nothing Special   »   [go: up one dir, main page]

BR112012028887A2 - associação de inibidores de xantina oxidase e antagonistas receptores de angiotensina ii e uso dos mesmos - Google Patents

associação de inibidores de xantina oxidase e antagonistas receptores de angiotensina ii e uso dos mesmos

Info

Publication number
BR112012028887A2
BR112012028887A2 BR112012028887A BR112012028887A BR112012028887A2 BR 112012028887 A2 BR112012028887 A2 BR 112012028887A2 BR 112012028887 A BR112012028887 A BR 112012028887A BR 112012028887 A BR112012028887 A BR 112012028887A BR 112012028887 A2 BR112012028887 A2 BR 112012028887A2
Authority
BR
Brazil
Prior art keywords
angiotensin
combination
receptor antagonists
xanthine oxidase
oxidase inhibitors
Prior art date
Application number
BR112012028887A
Other languages
English (en)
Inventor
Carlo Alberto Maggi
Francesco Melani
Sandro Giuliani
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42753377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012028887(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of BR112012028887A2 publication Critical patent/BR112012028887A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

associação de inibidores de xantina oxidase e antagonistas receptores de angiotensina ii e uso dos mesmos a presente invensão refere-se a uma associação de principios ativos ,isto é ,de um inibidor de xantina oxidase com um ou mais antagonistas receptores de angiotensina ii,composições farmacêuticas compreendendo os ditos princípios ativos para o uso em um tratamento terapêutico em seres humanos ou animais e métodos para a preparação dos mesmos.
BR112012028887A 2010-05-10 2011-05-09 associação de inibidores de xantina oxidase e antagonistas receptores de angiotensina ii e uso dos mesmos BR112012028887A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2010A000232A IT1400311B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
PCT/EP2011/057438 WO2011141431A1 (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof

Publications (1)

Publication Number Publication Date
BR112012028887A2 true BR112012028887A2 (pt) 2016-07-26

Family

ID=42753377

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028887A BR112012028887A2 (pt) 2010-05-10 2011-05-09 associação de inibidores de xantina oxidase e antagonistas receptores de angiotensina ii e uso dos mesmos

Country Status (23)

Country Link
US (1) US20130131128A1 (pt)
EP (1) EP2568982B1 (pt)
JP (1) JP2013526503A (pt)
KR (1) KR20130101447A (pt)
CN (1) CN103037861A (pt)
AR (1) AR081376A1 (pt)
AU (1) AU2011252151A1 (pt)
BR (1) BR112012028887A2 (pt)
CA (1) CA2798573A1 (pt)
CL (1) CL2012003143A1 (pt)
CO (1) CO6640306A2 (pt)
EA (1) EA201201528A1 (pt)
EC (2) ECSP12012332A (pt)
IL (1) IL222927A0 (pt)
IT (1) IT1400311B1 (pt)
MA (1) MA34297B1 (pt)
MX (1) MX2012013054A (pt)
NZ (1) NZ603414A (pt)
PE (1) PE20130812A1 (pt)
SG (1) SG185474A1 (pt)
TW (1) TW201206432A (pt)
WO (1) WO2011141431A1 (pt)
ZA (1) ZA201209295B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3028371B1 (fr) * 2014-11-06 2016-11-18 Bull Sas Procede de surveillance et de controle deportes d'un cluster utilisant un reseau de communication de type infiniband et programme d'ordinateur mettant en oeuvre ce procede
KR102284764B1 (ko) 2020-07-08 2021-08-04 주식회사 우드메탈 멀티빔구조를 통한 부속의 결속이 용이한 칸막이

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2073981C (en) 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
ES2371786T5 (es) 1998-06-19 2019-04-22 Teijin Ltd Polimorfo de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxílico y método para su producción
WO2002041890A1 (fr) 2000-11-21 2002-05-30 Sankyo Company, Limited Compositions medicinales
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
PL377344A1 (pl) 2003-01-31 2006-01-23 Sankyo Company, Limited Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
WO2007062028A2 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
US20080269226A1 (en) 2006-11-13 2008-10-30 Christopher Lademacher Methods for Preserving Renal Function Using Xanthine Oxidoreductase Inhibitors

Also Published As

Publication number Publication date
EP2568982A1 (en) 2013-03-20
ITRM20100232A1 (it) 2011-11-11
IL222927A0 (en) 2012-12-31
ECSP12012331A (es) 2013-02-28
CL2012003143A1 (es) 2013-06-21
MA34297B1 (fr) 2013-06-01
CN103037861A (zh) 2013-04-10
US20130131128A1 (en) 2013-05-23
CO6640306A2 (es) 2013-03-22
EP2568982B1 (en) 2014-04-02
IT1400311B1 (it) 2013-05-24
AR081376A1 (es) 2012-08-29
CA2798573A1 (en) 2011-11-17
KR20130101447A (ko) 2013-09-13
WO2011141431A1 (en) 2011-11-17
TW201206432A (en) 2012-02-16
AU2011252151A1 (en) 2012-11-29
SG185474A1 (en) 2012-12-28
NZ603414A (en) 2014-03-28
ZA201209295B (en) 2013-08-28
EA201201528A1 (ru) 2013-04-30
MX2012013054A (es) 2013-03-05
JP2013526503A (ja) 2013-06-24
ECSP12012332A (es) 2013-02-28
PE20130812A1 (es) 2013-08-08

Similar Documents

Publication Publication Date Title
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
ECSP13012618A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
BR112014018910A8 (pt) Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
PA8849701A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico
BR112013011184A2 (pt) composições e métodos para tratamento de mielofibrose
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
EA201290976A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
BR112018007947A2 (pt) uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash
PH12016502353A1 (en) Pharmaceutical composition
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112013008211A8 (pt) Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
TW201613577A (en) Pharmaceutical combinations
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
UY33663A (es) Derivados amínicos para el tratamiento de trastornos proliferativos de la piel
BR112012021445B8 (pt) formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
BR112018000568A2 (pt) antagonistas do receptor 5-ht6 para uso no tratamento da doença de alzheimer com apatia como comorbidade
BR112012028887A2 (pt) associação de inibidores de xantina oxidase e antagonistas receptores de angiotensina ii e uso dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]